News about BioNTech

BioNTech (NASDAQ: BNTX) held 16.6 billion euros in cash, cash equivalents and securities at the end of the second quarter and announced a share repurchase program of up to $1 billion. Its only commercialized product is the COVID-19 vaccine Comirnaty, developed with Pfizer, while the company aims to become a multiproduct oncology business by 2030. It reports 14 ongoing pivotal trials, including seven evaluating pumitamig, a candidate developed with Bristol Myers Squibb. Of the 20 analysts covering the stock, 13 rate it a strong buy and the rest a hold, with target prices implying 5% to 64% upside (average 39%). The stock trades at a price-to-sales ratio of 7, and the article flags trial failures, approval delays and declining COVID-19 vaccine revenue as key risks.